MBX Biosciences reports Q2 2026 results, canvuparatide Phase 3 recruiting

MBX Biosciences reported second quarter 2026 financial results and pipeline updates on August 6, 2026, according to an 8-K filing.

The company presented full Phase 2 results and one-year open-label extension data for once-weekly canvuparatide at ENDO 2026. The data showed sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy through one year, with findings consistent with restoration of systemic PTH activity through normalization of serum calcium, reduction of urine calcium excretion and restoration of bone metabolism, along with a safety and pharmacokinetic profile the company said supports once-weekly dosing.¹ The company said it remains on track to begin a Phase 3 pivotal trial of once-weekly canvuparatide in chronic hypoparathyroidism in the third quarter of 2026¹, with clinical trial sites already activated and participants being recruited and screened¹. The trial is named "oPTimize."

For its obesity pipeline, MBX disclosed preliminary blinded Phase 1 data on MBX 4291, a GLP-1/GIP receptor agonist peptide prodrug. In the first multiple ascending dose Part B cohort, mean weight loss was 7% (range, 0–16%) at eight weeks among 8 participants, including 2 on placebo, and the drug was tolerated without notable issues over that period.¹ The company expects data from the first cohort of the 12-week Part C portion of the trial in the fourth quarter of 2026.¹

MBX also nominated two new development candidates: MBX 6180, a GLP-1/GIP/glucagon triple agonist prodrug combining all three receptor activities in one construct¹, and, in May 2026, MBX 5765, an amycretin prodrug combining GLP-1, GIP, GCG, and dual amylin/calcitonin receptor agonist activity¹.

Financially, the company reported $418.6 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it expects will fund operations into 2029¹. Research and development expenses were $31.0 million for the quarter, up from $17.7 million a year earlier¹, and net loss was $37.1 million compared to $19.4 million in the prior-year period¹.